Shandong Xinhua Pharmaceutical Co., Ltd

Hualu Network Group 中文版

Investor Relation

Information transparency and trust in peers

Investor Relation

INTERIM REPORT

2026 Interim Report

Overseas Regulatory Announcement-Announcement on Levocarnitine Oral Solution having obtained Drug Registration Certificate

Overseas Regulatory Announcement-Announcement on Donepezil Hydrochloride Orally Disintegrating Tablets of Subsidiary Having Obtained Drug Registration Certificate

Overseas Regulatory Announcement-Announcement on Magnesium Sulfate, Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution Having Obtained Drug Registration Certificate

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 August 2026

Overseas Regulatory Announcement-Announcement on Azithromycin Tablets Having Passed the Generics Consistency Evaluation

Overseas Regulatory Announcement-Announcement on Dapoxetine Hydrochloride Tablets having obtained Drug Registration Certificate

Overseas Regulatory Announcement-Announcement on Dapagliflozin Tablets having obtained Drug Registration Certificate

Announcement Notice of Board Meeting

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 July 2026

总条数: 96条

＜ 1 2 3 ... 10 ＞

跳转到: 页